Novartis Historical Cash Flow
| NVS Stock | USD 97.13 0.04 0.04% |
Analysis of Novartis cash flow over time is an excellent tool to project Novartis AG ADR future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 323.3 M or Depreciation of 4.3 B as it is a great indicator of Novartis ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Novartis AG ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novartis AG ADR is a good buy for the upcoming year.
Novartis |
About Novartis Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Novartis balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Novartis's non-liquid assets can be easily converted into cash.
Novartis Cash Flow Chart
Novartis Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Novartis AG ADR Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Novartis' Change In Cash is comparatively stable compared to the past year. Other Cashflows From Financing Activities is likely to gain to about 323.3 M in 2024, whereas Free Cash Flow is likely to drop slightly above 9.1 B in 2024. Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Novartis AG ADR to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Novartis operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Novartis AG ADR financial statement analysis. It represents the amount of money remaining after all of Novartis AG ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Novartis' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novartis' Change In Cash is comparatively stable compared to the past year. Other Cashflows From Financing Activities is likely to gain to about 323.3 M in 2024, whereas Free Cash Flow is likely to drop slightly above 9.1 B in 2024.
Novartis cash flow statement Correlations
Click cells to compare fundamentals
Novartis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novartis cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | (5.5B) | (2.8B) | (3.1B) | (10.7B) | (8.7B) | (8.3B) | |
| Change In Cash | (2.2B) | (1.5B) | 2.7B | (4.9B) | 5.9B | 6.2B | |
| Free Cash Flow | 11.4B | 11.1B | 12.1B | 11.6B | 11.7B | 9.1B | |
| Change In Working Capital | 199M | (291M) | 241M | (1.0B) | (369M) | (350.6M) | |
| Begin Period Cash Flow | 13.3B | 11.1B | 9.7B | 12.4B | 7.5B | 7.4B | |
| Other Cashflows From Financing Activities | 50M | (149M) | 94M | 466M | 192M | 323.3M | |
| Depreciation | 5.8B | 6.5B | 6.1B | 7.2B | 8.3B | 4.3B | |
| Other Non Cash Items | (2.1B) | (3.1B) | (18.2B) | (1.1B) | (3.4B) | (3.6B) | |
| Capital Expenditures | 2.3B | 2.6B | 3.0B | 2.7B | 2.8B | 2.6B | |
| Total Cash From Operating Activities | 13.6B | 13.7B | 15.1B | 14.2B | 14.5B | 11.7B | |
| Net Income | 7.1B | 8.1B | 24.0B | 7.0B | 8.6B | 8.8B | |
| Total Cash From Financing Activities | (13.6B) | (2.2B) | (16.3B) | (20.6B) | (14.3B) | (13.6B) | |
| End Period Cash Flow | 11.1B | 9.7B | 12.4B | 7.5B | 13.4B | 7.7B | |
| Change To Inventory | (382M) | (543M) | 81M | (830M) | (546M) | (518.7M) | |
| Dividends Paid | 6.6B | 7.0B | 7.4B | 7.5B | 7.3B | 5.0B | |
| Other Cashflows From Investing Activities | (1.2B) | (186M) | (57M) | 4.1B | 4.8B | 5.0B | |
| Change To Liabilities | 553M | (324M) | (21M) | (48M) | (43.2M) | (41.0M) | |
| Stock Based Compensation | 758M | 738M | 736M | 823M | 865M | 592.7M | |
| Change To Account Receivables | (980M) | 137M | (389M) | (589M) | (1.5B) | (1.4B) | |
| Investments | (2.2B) | (13.2B) | 6.8B | 1.5B | 5.9B | 6.2B | |
| Net Borrowings | (5.0B) | 7.1B | (6.0B) | (2.6B) | (2.3B) | (2.2B) | |
| Total Cashflows From Investing Activities | (2.2B) | (13.2B) | 4.2B | 1.5B | 5.6B | 5.9B | |
| Change To Operating Activities | 84M | (2.0B) | (549M) | (421M) | (484.2M) | (508.4M) | |
| Change To Netincome | (2.1B) | 2.8B | (13.5B) | 3.7B | 3.3B | 3.5B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.215 | Dividend Share 3.919 | Earnings Share 4.4 | Revenue Per Share 23.168 | Quarterly Revenue Growth 0.097 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.